Oct 1 (Reuters) - Johnson & Johnson ( JNJ ) said on

Tuesday it will invest more than $2 billion to build a new

manufacturing facility in Wilson, North Carolina, aiding

production of new therapies.

The new facility will expand J&J's production of biologic

medicines to treat cancer, immunity-related and neurological

diseases, the company said.

The drugmaker aims to launch or file for more than 70 new

therapies and expanded treatment options for patients by 2030.

J&J is investing in capacity to ensure a resilient supply

chain for the future, said Dapo Ajayi, vice president at J&J's

innovative medicine supply chain.

The company expects to commence construction of the facility

in the first half of 2025, J&J said, adding that it will employ

about 400 full-time staff when it is fully operational.